James Liao named as new candidate to helm Taiwan's Academia Sinica

Academia Sinica

Academic researcher James Liao has been named as the choice to become the new head of Taiwan's Academia Sinica, closing a chapter at the top academic research body that saw potential future Nobel Prize winner Wong Chi-huey resign last month under a cloud for a controversial sale of shares in biotech OBI Pharma by his daughter.

China Post reported that Taiwan's new president and biotech booster Tsai Ing-wen has selected Liao to take the helm as the 11th president of the respected research academy with a formal announcement due later this week. The board of the institute is expected to first confirm the appointment.

Liao is currently in the United States where he holds a top academic post at the Institute for Genomics and Proteomics of the University of California, Los Angeles.


[Infographic] Machine Learning, Statistics and Optimizing Outcomes

In our infographic, we outline the potential of fusing machine learning and statistics algorithms together to more efficiently analyze clinical trial data output and ultimately revolutionize clinical research.

His area of research covers metabolic engineering, synthetic biology and systems biology. He earned a doctorate from the University of Wisconsin, according to China Post.

Wong resigned last month after issuing an apology that said he was responsible for the sale of 3 million shares in OBI Pharma just before data was published from the company's key cancer drug showed it had failed a key trial.

- here's the story from China Post



Suggested Articles

Think you’re busy? Take a look at Pfizer’s commercial team for oncology, which is currently juggling eight launches. And that’s just in the U.S.

Opioid lawsuits from cities, counties and states have left legal experts confused about next steps, and a "negotiating class" proposal isn't…

For years, Roche’s blockbuster oncology troika dominated sales stateside and abroad. For Herceptin and Avastin, those landmark years could be over.